What is the diagnosis indicated by a thyroid‑stimulating hormone level of 12.9 µIU/mL and a free thyroxine level of 0.74 ng/dL?

Primary Hypothyroidism (Overt)

Your laboratory results indicate overt primary hypothyroidism requiring immediate levothyroxine therapy. A TSH of 12.90 mIU/L combined with a free T4 of 0.74 ng/dL (below the normal range of approximately 0.9–1.9 ng/dL) definitively establishes this diagnosis 1, 2.

---

Diagnostic Interpretation

• TSH >10 mIU/L with low free T4 confirms overt primary hypothyroidism, distinguishing this from subclinical disease where free T4 remains normal 1, 2.
• The elevated TSH reflects your pituitary gland attempting to stimulate an underperforming thyroid gland, while the low T4 confirms inadequate thyroid hormone production 1, 2.
• This pattern indicates primary thyroid gland failure rather than pituitary or hypothalamic dysfunction (central hypothyroidism), where TSH would be inappropriately low or normal despite low T4 3, 2.

---

Immediate Treatment Algorithm

Step 1: Exclude Adrenal Insufficiency Before Starting Levothyroxine

• Measure morning (8 AM) serum cortisol and ACTH before initiating levothyroxine, as starting thyroid hormone in unrecognized adrenal insufficiency can precipitate life-threatening adrenal crisis 1.
• If cortisol is low or clinical features suggest adrenal insufficiency (hypotension, hyponatremia, unexplained symptoms), start hydrocortisone 20 mg morning and 10 mg afternoon for at least one week before levothyroxine 1.
• This precaution is critical because thyroid hormone accelerates cortisol metabolism, potentially unmasking occult adrenal failure 1.

Step 2: Initiate Levothyroxine Based on Age and Cardiac Status

For patients <70 years without cardiac disease:

• Start levothyroxine at full replacement dose of approximately 1.6 mcg/kg/day based on ideal body weight 1.
• This approach rapidly normalizes thyroid function and prevents prolonged exposure to hypothyroid complications 1.

For patients ≥70 years OR with any cardiac disease:

• Start at a conservative dose of 25–50 mcg/day and titrate gradually by 12.5–25 mcg increments every 6–8 weeks 1.
• Rapid normalization in these populations risks unmasking cardiac ischemia, precipitating myocardial infarction, heart failure, or fatal arrhythmias 1.
• Elderly patients with coronary disease face increased risk of cardiac decompensation even with therapeutic levothyroxine doses 1.

Step 3: Monitoring and Dose Adjustment

• Recheck TSH and free T4 in 6–8 weeks after starting therapy, as this interval is required to reach steady-state hormone levels 1.
• Target TSH within the reference range of 0.5–4.5 mIU/L with normal free T4 1, 2.
• Continue dose adjustments by 12.5–25 mcg increments every 6–8 weeks until TSH normalizes 1.
• Once stable, monitor TSH every 6–12 months or sooner if symptoms change 1.

---

Clinical Significance and Risks of Untreated Disease

Cardiovascular Consequences

• Hypothyroidism causes cardiac dysfunction including delayed myocardial relaxation, reduced cardiac output, and increased systemic vascular resistance 1.
• TSH >10 mIU/L is associated with diastolic heart failure, hypertension, and adverse cardiovascular outcomes 3, 1.
• Untreated hypothyroidism increases cardiovascular mortality risk, particularly in patients with pre-existing heart disease 1.

Metabolic Complications

• Elevated TSH >10 mIU/L correlates with dyslipidemia, specifically elevated total cholesterol, LDL cholesterol, and triglycerides 1.
• Treatment with levothyroxine improves lipid profiles and reduces cardiovascular risk 1.

Progression Risk

• Patients with TSH >10 mIU/L have approximately 5% annual risk of worsening thyroid function if left untreated 1.
• Delaying treatment allows continued thyroid destruction and worsening symptoms 1.

Quality of Life Impact

• Overt hypothyroidism causes severe fatigue, weight gain, cold intolerance, constipation, cognitive slowing ("brain fog"), depression, and hair loss 1.
• These symptoms significantly impair daily functioning and quality of life 1.
• Treatment typically improves symptoms within 6–8 weeks of achieving target TSH 1.

---

Critical Pitfalls to Avoid

Do Not Delay Treatment for Confirmatory Testing

• With TSH 12.90 and low T4, treatment should begin immediately—this is overt disease, not subclinical hypothyroidism requiring confirmation 1.
• The 30–60% spontaneous normalization rate applies only to mild TSH elevations (4.5–10 mIU/L) with normal T4, not to overt hypothyroidism 1.

Never Start Levothyroxine Before Excluding Adrenal Insufficiency

• In suspected central hypothyroidism or patients with autoimmune disease, always rule out adrenal insufficiency first by measuring morning cortisol and ACTH 1.
• Starting thyroid hormone before adequate glucocorticoid coverage can trigger adrenal crisis, a life-threatening emergency 1.

Avoid Overtreatment

• Approximately 25% of patients on levothyroxine are unintentionally overtreated with TSH suppressed below 0.1 mIU/L 1.
• TSH suppression increases risk of atrial fibrillation (3–5 fold), osteoporosis, fractures, and cardiovascular mortality, especially in patients >60 years 1.
• If TSH falls below 0.1 mIU/L during treatment, reduce levothyroxine by 25–50 mcg immediately 1.

Do Not Use Full Replacement Dose in Elderly or Cardiac Patients

• Starting at 1.6 mcg/kg/day in patients >70 years or with cardiac disease can precipitate myocardial infarction or fatal arrhythmias 1.
• Always use conservative dosing (25–50 mcg/day) and slow titration in these populations 1.

---

Additional Diagnostic Considerations

Identify Underlying Etiology

• Measure anti-TPO antibodies to confirm autoimmune thyroiditis (Hashimoto's disease), the most common cause of primary hypothyroidism 1, 4.
• Anti-TPO antibodies are present in >99% of Hashimoto's cases and predict higher progression risk 4.
• Positive antibodies warrant screening for other autoimmune conditions including type 1 diabetes, celiac disease, pernicious anemia, and Addison's disease 1, 4.

Screen for Associated Conditions

• Check complete blood count to screen for anemia, which commonly coexists with hypothyroidism and contributes to fatigue 1.
• Measure fasting lipid panel, as hypothyroidism causes dyslipidemia that improves with treatment 1.
• Assess renal function (creatinine, eGFR), as hypothyroidism can impair kidney function 1.

---

Special Population Considerations

Women Planning Pregnancy

• If planning pregnancy, optimize thyroid function immediately, targeting TSH <2.5 mIU/L before conception 1.
• Untreated maternal hypothyroidism increases risk of preeclampsia, low birth weight, miscarriage, and permanent neurodevelopmental deficits in the child 1.
• Levothyroxine requirements typically increase 25–50% during pregnancy, requiring dose adjustment upon pregnancy confirmation 1.

Patients on Immune Checkpoint Inhibitors

• Thyroid dysfunction occurs in 6–9% of patients on anti-PD-1/PD-L1 therapy and 16–20% on combination immunotherapy 1.
• Even with overt hypothyroidism, immunotherapy can usually continue without interruption while managing thyroid dysfunction 1.

---

Evidence Quality

• The recommendation for immediate levothyroxine treatment in overt hypothyroidism (TSH >10 mIU/L with low T4) is supported by fair-quality evidence from expert panels and observational studies 1.
• Treatment prevents cardiovascular complications, improves symptoms and lipid profiles, and reduces progression risk 1.
• The evidence supporting specific dosing strategies (full replacement vs. conservative initiation) is based on decades of clinical experience and safety data 1.